Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) traded down 7.6% on Thursday . The stock traded as low as $6.75 and last traded at $6.80. 1,574,327 shares traded hands during trading, an increase of 18% from the average session volume of 1,335,360 shares. The stock had previously closed at $7.36.

Several analysts have weighed in on the company. ValuEngine raised Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. BidaskClub cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. Maxim Group set a $9.00 price objective on Keryx Biopharmaceuticals and gave the company a “buy” rating in a research report on Thursday, July 27th. Cowen and Company reaffirmed a “hold” rating on shares of Keryx Biopharmaceuticals in a research report on Saturday, June 17th. Finally, Zacks Investment Research cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 8th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company’s stock. Keryx Biopharmaceuticals has a consensus rating of “Hold” and a consensus target price of $7.48.

The stock’s 50-day moving average is $7.00 and its 200-day moving average is $6.49. The firm’s market capitalization is $853.81 million.

Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.60). The company had revenue of $15.10 million during the quarter, compared to the consensus estimate of $14.51 million. Keryx Biopharmaceuticals had a negative return on equity of 2,902.87% and a negative net margin of 431.89%. Keryx Biopharmaceuticals’s revenue was up 62.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.42) earnings per share. Equities research analysts predict that Keryx Biopharmaceuticals, Inc. will post ($1.23) EPS for the current fiscal year.

Hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. grew its stake in Keryx Biopharmaceuticals by 4.2% in the 2nd quarter. Principal Financial Group Inc. now owns 14,759 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 590 shares in the last quarter. OZ Management LP bought a new position in shares of Keryx Biopharmaceuticals during the first quarter valued at approximately $109,000. Raymond James Financial Services Advisors Inc. boosted its stake in shares of Keryx Biopharmaceuticals by 51.8% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 16,495 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 5,628 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Keryx Biopharmaceuticals during the first quarter valued at approximately $141,000. Finally, Legal & General Group Plc boosted its stake in shares of Keryx Biopharmaceuticals by 1.2% during the first quarter. Legal & General Group Plc now owns 25,985 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 300 shares in the last quarter. Institutional investors and hedge funds own 65.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Keryx Biopharmaceuticals, Inc. (KERX) Shares Down 7.6%” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/16/keryx-biopharmaceuticals-inc-kerx-shares-down-7-6.html.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Receive News & Stock Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related stocks with our FREE daily email newsletter.